**6. Conclusions**

Around 50% of patients with STEMI have MVCAD that significantly worsens prognosis. There are three treatment approaches to these patients: culprit vessel intervention only, with ischemia‐based PCI of non‐IRA, MV stenting either at the time of PPCI or as a planned, staged procedure. Both MPS and MSS have evidence base and are approved by the current clinical guidelines. Treatment of culprit vessel only leads to worse outcomes. Complete revascularization, achievable through either MPS or MSS, is the key aim that was confirmed by our single‐center registry study of initial and residual SYNTAX score. However, the choice between MPS and MSS is a crucially important issue. Here we defined the risk factors of adverse outcomes after either of these strategies and developed an original calculator for the choice of an optimal stenting strategy. Moreover, we carried out a randomized clinical trial and revealed that results of revascularization in patients with STEMI and MVCAD may be improved by using the latest generation DES such as Resolute Integrity™ Stent.

Hence, we justify the use of personalized approach for the optimal revascularization strategy in patients with STEMI and MVCAD using the latest generation of DES with choosing MPS or MSS according to our original calculator.
